TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease
Brief Summary: The primary objective of this study is to investigate the effects of a theoretically driven, highly challenging exercise program (balance and strengthening exercises) in reducing fall rate, improving balance and reducing fear of falling in persons with Parkinson's disease.

In this pilot, randomized, cross-over study, 32 participants with Parkinson disease will be randomly assigned to either an early start (immediately following enrollment) or late start (3 months after enrollment) multifactorial exercise program which will meet 2 times per week for 1.5 hours over 3 months. The exercise program will consist of balance and strengthening exercises which will be individualized depending on the ability of each participant. Fall rate, balance, walking ability, fear of falling, mood, anxiety, and quality of life will be measured prior to the start, at 3 months and 6 months after enrollment. Subjects will be enrolled for 6-7 months.


Options:
A: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Early Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Arm Label: Late Multi-Ex-PD; Type: EXPERIMENTAL; Interventions: Behavioral: Balance & Strengthening Exercises | Intervention Type: BEHAVIORAL; Name: Balance & Strengthening Exercises; Assigned to Arm(s): Early Multi-Ex-PD, Late Multi-Ex-PD
C: Arm Label: IPX066; Type: EXPERIMENTAL; Interventions: Drug: IPX066, Drug: IR CD-LD | Arm Label: IR CD-LD; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPX066, Drug: IR CD-LD | Intervention Type: DRUG; Name: IPX066; Assigned to Arm(s): IPX066, IR CD-LD | Intervention Type: DRUG; Name: IR CD-LD; Assigned to Arm(s): IPX066, IR CD-LD
D: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi | Arm Label: B. Strength training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Strength training | Arm Label: C. Low-Impact; Type: OTHER; Interventions: Behavioral: Low-Impact Exercise Control | Intervention Type: BEHAVIORAL; Name: Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): B. Strength training | Intervention Type: BEHAVIORAL; Name: Low-Impact Exercise Control; Assigned to Arm(s): C. Low-Impact

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automatic Oxygen Administration in Spontaneous Ventilation During the Hypoxemic Acute Respiratory Distress in Infants and Children
Brief Summary: The aim of the study is to assess the use feasibility of the FreeO2 system so as to deliver automatically oxygen in infants and children admitted at hospital for hypoxemic acute respiratory distress.

In healthy volunteers adults, FreeO2 system provided a better control of the oxygen saturation in function of designed target, reducing the desaturation time and hyperoxia. Our hypothesis is that FreeO2 system use is feasible in infants and children with hypoxemic acute respiratory distress. We think FreeO2 will provide a better control of the oxygen saturation, a faster oxygen weaning than classical way (Rotameter). In addition, FreeO2 could reduce the number of intervention by nurses.


Options:
A: Arm Label: Experimental: device FreeO.; Type: EXPERIMENTAL; Interventions: Device: FreeO2 v2.0 automatic adjustment | Arm Label: Manual oxygenation; Type: ACTIVE_COMPARATOR; Interventions: Device: FreeO2 v2.0 data collecting | Intervention Type: DEVICE; Name: FreeO2 v2.0 automatic adjustment; Assigned to Arm(s): Experimental: device FreeO. | Intervention Type: DEVICE; Name: FreeO2 v2.0 data collecting; Assigned to Arm(s): Manual oxygenation
B: Intervention Type: DRUG; Name: Caffeine citrate injection; Assigned to Arm(s): N/A
C: Arm Label: Manual oxygen control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Closed-loop automated oxygen control; Type: OTHER; Interventions: Device: Closed-loop automated oxygen control (Oxygenie, SLE 6000) | Intervention Type: DEVICE; Name: Closed-loop automated oxygen control (Oxygenie, SLE 6000); Assigned to Arm(s): Closed-loop automated oxygen control
D: Arm Label: Automatic Oxygen Control; Type: EXPERIMENTAL; Interventions: Device: Automatic Oxygen control | Arm Label: Manual oxygen control; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Oxygen Control | Intervention Type: DEVICE; Name: Automatic Oxygen control; Assigned to Arm(s): Automatic Oxygen Control | Intervention Type: OTHER; Name: Manual Oxygen Control; Assigned to Arm(s): Manual oxygen control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial
Brief Summary: The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.


Options:
A: Arm Label: Carbetocin 10mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 20mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 40mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 60mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 140mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg, Carbetocin 10mcg, Carbetocin 120mcg, Carbetocin 140mcg, Carbetocin 20mcg, Carbetocin 40mcg, Carbetocin 60mcg, Carbetocin 80mcg
B: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
D: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial
Brief Summary: The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: Misoprostol group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: oxytocin only group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol group | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic group | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin only group
D: Arm Label: Intravenous tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml | Arm Label: Intramuscular tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid Injectable Product | Arm Label: Oral liquid tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid Oral Solution | Arm Label: No tranexamic acid; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml; Assigned to Arm(s): Intravenous tranexamic acid | Intervention Type: DRUG; Name: Tranexamic Acid Oral Solution; Assigned to Arm(s): Oral liquid tranexamic acid | Intervention Type: DRUG; Name: Tranexamic Acid Injectable Product; Assigned to Arm(s): Intramuscular tranexamic acid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial
Brief Summary: The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
D: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.


Options:
A: Arm Label: BTX-A-HAC NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): BTX-A-HAC NG | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo
C: Arm Label: Dose A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose B; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose C; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Dose D; Type: ACTIVE_COMPARATOR; Interventions: Biological: Active Comparator botulinum toxin | Arm Label: Dose E; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Comparator | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): Dose A, Dose B, Dose C | Intervention Type: BIOLOGICAL; Name: Active Comparator botulinum toxin; Assigned to Arm(s): Dose D | Intervention Type: BIOLOGICAL; Name: Placebo Comparator; Assigned to Arm(s): Dose E
D: Arm Label: DaxibotulinumtoxinA 40 units; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxins, Type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebos | Intervention Type: BIOLOGICAL; Name: Botulinum Toxins, Type A; Assigned to Arm(s): DaxibotulinumtoxinA 40 units | Intervention Type: BIOLOGICAL; Name: Placebos; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome
Brief Summary: Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)


Options:
A: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
D: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin + heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Heparin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin + heparin | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Aspirin + heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome
Brief Summary: Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: dalteparin sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin sodium | Intervention Type: DRUG; Name: dalteparin sodium; Assigned to Arm(s): dalteparin sodium
B: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
C: Arm Label: Multivitamin supplement; Type: OTHER; Interventions: Dietary Supplement: Multivitamin supplement | Arm Label: Multivitamin supplement + dalteparin sodium; Type: EXPERIMENTAL; Interventions: Drug: Fragmin P Forte (dalteparin sodium) | Intervention Type: DRUG; Name: Fragmin P Forte (dalteparin sodium); Assigned to Arm(s): Multivitamin supplement + dalteparin sodium | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement; Assigned to Arm(s): Multivitamin supplement
D: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome
Brief Summary: Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)


Options:
A: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Low molecular weight heparin and low dose aspirin | Arm Label: b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose aspirin | Intervention Type: DRUG; Name: Low molecular weight heparin and low dose aspirin; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Low dose aspirin; Assigned to Arm(s): b
C: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group
D: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome
Brief Summary: Evaluation of shifting to oral vitamin K antagonist after the first trimester instead of using low molecular weight heparin (LMWH) throughout pregnancy in pregnant women with antiphospholipid syndrome (APS)


Options:
A: Intervention Type: DRUG; Name: Low dose steroids; Assigned to Arm(s): N/A
B: Arm Label: Low molecular weight heparin; Type: N/A; Interventions: Drug: low molecular weight heparin (enoxeparine) | Intervention Type: DRUG; Name: low molecular weight heparin (enoxeparine); Assigned to Arm(s): Low molecular weight heparin
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic-acid (aspirin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Folic acid | Intervention Type: DRUG; Name: acetylsalicylic-acid (aspirin); Assigned to Arm(s): Aspirin | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid; Assigned to Arm(s): Placebo
D: Arm Label: Enoxaparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Warfarin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin group | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Brief Summary: This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in subjects with hereditary angioedema (HAE). Eligible subjects will be randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical outcomes, and the safety and tolerability of each dose of BCX4161 compared to placebo.


Options:
A: Arm Label: BCX4161 300 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161, Drug: Placebo | Arm Label: BCX4161 500 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161 | Arm Label: Placebo three times daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 300 mg three times daily, BCX4161 500 mg three times daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BCX4161 300 mg three times daily, Placebo three times daily
B: Arm Label: BCX4161; Type: ACTIVE_COMPARATOR; Interventions: Drug: BCX4161 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf
D: Arm Label: Open-label C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): Open-label C1INH-nf

Answer: A